Glyphic Biotechnologies is pioneering the first truly de novo, high-throughput proteome sequencing technology — capable of distinguishing all 20 amino acids and post-translational modifications (PTMs) with single-molecule precision.
Founded in 2021 and based in Berkeley, California, Glyphic is on a mission to reshape the field of proteomics fundamentally.
At the heart of their innovation is ProSE™ (Protein Sequencing by Expansion) — a groundbreaking platform designed for accuracy, scalability, and accessibility.
They believe proteome sequencing will be one of the defining scientific breakthroughs of the 21st century — powering first-in-class therapies and offering transformative insight into the building blocks of life itself.
